Kewaunee Scientific
Kewaunee Scientific's revenue rose 17.3% to $282 million in fiscal 2026. Its operating margin was 5.9%, down from 7.4% a year earlier. Free cash flow was $15 million, up 16.5%. The diluted share count rose 0.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2017 to 2026, earnings per share grew 7.6% a year and net income 8.8% a year, as new shares raised the share count by 11% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 4 | 8 | 23 | 15 | 10 |
| Debt incl. finance leases | 2 | 4 | 3 | 39 | 20 |
| Net debt (negative means net cash) | −3 | −4 | −20 | 24 | 11 |
| Net debt to EBITDA | −15.5x | −0.5x | −0.9x | 1.1x | 0.5x |
| Debt to equity | 0.1x | 0.1x | 0.1x | 0.6x | 0.3x |
| Interest coverage | −4.1x | 3.1x | 10.2x | 5.5x | 4.3x |
| Current ratio | 2.2x | 2.2x | 2.4x | 2.2x | 2.2x |
| Quick ratio | 1.6x | 1.6x | 1.9x | 1.6x | 1.6x |
Cash flow
Projections
Project Kewaunee Scientific's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Kewaunee Scientific shares on the open market, and 2 insiders sold $293,169.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 7, 2026 | Thomas David Hull IIIPresident, CEO, Director | Sold | 2,177 | $37.50 | $81,638 | Form 4 |
| Jan 6, 2026 | Donald T. Gardner IIIChief Financial Officer | Sold | 2,000 | $37.57 | $75,140 | Form 4 |
| Dec 31, 2025 | Thomas David Hull IIIPresident, CEO, Director | Sold | 629 | $37.66 | $23,688 | Form 4 |
| Dec 30, 2025 | Thomas David Hull IIIPresident, CEO, Director | Sold | 29 | $38.00 | $1,102 | Form 4 |
| Dec 29, 2025 | Thomas David Hull IIIPresident, CEO, Director | Sold | 884 | $38.01 | $33,601 | Form 4 |
| Dec 22, 2025 | Thomas David Hull IIIPresident, CEO, Director | Sold | 1,000 | $39.00 | $39,000 | Form 4 |
| Dec 17, 2025 | Thomas David Hull IIIPresident, CEO, Director | Sold | 1,000 | $39.00 | $39,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 5 of 9 | 4 of 9 |
| Rule of 40 | 0.3% | 23.3% | 22.5% |
| Altman Z'' | 5.54 | 4.32 | 4.78 |
| Accruals ratio | −0.6% | −2.0% | −4.8% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 7 of 9 | 5 of 9 | 4 of 9 |
Compare
Put Kewaunee Scientific side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Kewaunee Scientific | FY26 | 17.3% | 5.9% | 5.2% | 14.3% | 0.5x | 4 | |
| Acme United | FY25 | 1.1% | 7.5% | 3.9% | 9.4% | 0.4x | 7 | Compare |
| Interface | FY25 | 5.4% | 11.8% | 8.8% | 19.0% | 0.6x | 7 | Compare |
| ACCO Brands | FY25 | −8.5% | 6.0% | — | 5.6% | 4.7x | 7 | Compare |
| MSA Safety | FY25 | 3.7% | 19.8% | 15.8% | 17.3% | 0.9x | 6 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 139 | 158 | 146 | 148 | 148 | 169 | 220 | 204 | 240 | 282 |
| Revenue growth | 7.7% | 14.1% | −7.3% | 0.7% | −0.1% | 14.5% | 30.0% | −7.2% | 18.0% | 17.3% |
| Gross profit | 27 | 32 | 25 | 23 | 24 | 24 | 36 | 52 | 69 | 80 |
| Research and development | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | 6 | 10 | 2 | −2 | −1 | −3 | 5 | 18 | 18 | 17 |
| Net income | 4 | 5 | 2 | −5 | −4 | −6 | 1 | 19 | 11 | 10 |
| Diluted EPS (US$) | 1.66 | 1.90 | 0.55 | −1.70 | −1.33 | −2.20 | 0.25 | 6.38 | 3.83 | 3.22 |
| Diluted shares (millions) | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Cash flow | ||||||||||
| Cash from operations | 12 | 3 | 2 | 4 | 1 | −8 | −4 | 20 | 15 | 19 |
| Capital expenditure | 3 | 3 | 4 | 2 | 2 | 2 | 4 | 4 | 2 | 4 |
| Free cash flow | 9 | −0 | −2 | 2 | −1 | −10 | −8 | 15 | 13 | 15 |
| Dividends paid | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 12 | 10 | 11 | 4 | 5 | 4 | 8 | 23 | 15 | 10 |
| Debt incl. finance leases | 2 | 1 | 0 | 5 | 7 | 2 | 4 | 3 | 39 | 20 |
| Total assets | 81 | 85 | 87 | 84 | 89 | 119 | 119 | 135 | 195 | 178 |
| Total liabilities | 38 | 37 | 40 | 45 | 48 | 83 | 80 | 79 | 128 | 102 |
| Shareholders' equity | 44 | 48 | 47 | 38 | 41 | 36 | 37 | 55 | 64 | 75 |
| Margins and ratios | ||||||||||
| Gross margin | 19.2% | 20.4% | 17.3% | 15.9% | 16.3% | 14.3% | 16.2% | 25.6% | 28.6% | 28.5% |
| Operating margin | 4.7% | 6.3% | 1.4% | −1.6% | −0.9% | −1.5% | 2.4% | 9.0% | 7.4% | 5.9% |
| Net margin | 3.3% | 3.3% | 1.0% | −3.2% | −2.5% | −3.6% | 0.3% | 9.2% | 4.7% | 3.4% |
| Free cash flow margin | 6.5% | −0.1% | −1.2% | 1.1% | −1.0% | −5.8% | −3.6% | 7.5% | 5.2% | 5.2% |
| Rule of 40 (growth + FCF margin) | 14.2% | 13.9% | −8.4% | 1.8% | −1.1% | 8.7% | 26.4% | 0.3% | 23.3% | 22.5% |
| Return on capital | 12.8% | 15.4% | 4.3% | −4.8% | −2.5% | −5.4% | 7.9% | 51.8% | 22.0% | 14.3% |
| Return on equity | 11.1% | 11.6% | 3.2% | −11.0% | −9.2% | −15.9% | 2.0% | 40.7% | 19.1% | 13.8% |
| Return on assets | 5.9% | 6.4% | 1.8% | −5.5% | −4.2% | −5.9% | 0.6% | 14.8% | 6.9% | 5.2% |
| Net debt to EBITDA | −1.1x | −0.7x | −2.2x | 1.6x | 1.3x | −15.5x | −0.5x | −0.9x | 1.1x | 0.5x |